Literature DB >> 1378258

Mononuclear cell subsets and coronary artery lesions in Kawasaki disease.

S Furukawa1, T Matsubara, K Yabuta.   

Abstract

The peripheral blood mononuclear cell subsets in patients with Kawasaki disease and coronary artery lesions were investigated. Of the 106 patients 14 had lesions. Patients with Kawasaki disease and coronary artery lesions were found to have increased counts of CD14+ macrophages/monocytes compared with those of patients with Kawasaki disease without lesions. The absolute counts of CD14+ macrophages/monocytes form an important parameter to determine the severity of vascular damage during acute Kawasaki disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378258      PMCID: PMC1793803          DOI: 10.1136/adc.67.6.706

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  7 in total

1.  Expression of Fc epsilon R2/CD23 on peripheral blood macrophages/monocytes in Kawasaki disease.

Authors:  S Furukawa; T Matsubara; T Motohashi; S Nakachi; K Sasai; K Yabuta
Journal:  Clin Immunol Immunopathol       Date:  1990-08

2.  Serum soluble CD4 and CD8 levels in Kawasaki disease.

Authors:  S Furukawa; T Matsubara; K Tsuji; T Motohashi; K Okumura; K Yabuta
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

3.  Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-alpha and interleukin 6 in serum.

Authors:  S Furukawa; T Matsubara; K Yone; Y Hirano; K Okumura; K Yabuta
Journal:  Eur J Pediatr       Date:  1992-01       Impact factor: 3.183

4.  Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions.

Authors:  T Matsubara; S Furukawa; K Yabuta
Journal:  Clin Immunol Immunopathol       Date:  1990-07

5.  Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin.

Authors:  D Y Leung; J C Burns; J W Newburger; R S Geha
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

6.  Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease.

Authors:  D Y Leung; R S Cotran; E Kurt-Jones; J C Burns; J W Newburger; J S Pober
Journal:  Lancet       Date:  1989-12-02       Impact factor: 79.321

7.  High-dose intravenous gammaglobulin for Kawasaki disease.

Authors:  K Furusho; T Kamiya; H Nakano; N Kiyosawa; K Shinomiya; T Hayashidera; T Tamura; O Hirose; Y Manabe; T Yokoyama
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321

  7 in total
  20 in total

1.  Increased levels of circulating soluble CD14 in Kawasaki disease.

Authors:  S Takeshita; K Nakatani; H Tsujimoto; Y Kawamura; H Kawase; I Sekine
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  CD14+CD16+ monocyte subpopulation in Kawasaki disease.

Authors:  K Katayama; T Matsubara; M Fujiwara; M Koga; S Furukawa
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 3.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease.

Authors:  T Matsubara; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

4.  Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease.

Authors:  Haruyuki Makata; Takashi Ichiyama; Ryutaro Uchi; Tsuyoshi Takekawa; Tomoyo Matsubara; Susumu Furukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-08-01       Impact factor: 3.000

5.  Decreased interferon-gamma (IFN-gamma)-producing T cells in patients with acute Kawasaki disease.

Authors:  T Matsubara; K Katayama; T Matsuoka; M Fujiwara; M Koga; S Furukawa
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

6.  Increased frequency of immunoglobulin (Ig)A-secreting cells following Toll-like receptor (TLR)-9 engagement in patients with Kawasaki disease.

Authors:  L Giordani; M G Quaranta; A Marchesi; E Straface; D Pietraforte; A Villani; W Malorni; D Del Principe; M Viora
Journal:  Clin Exp Immunol       Date:  2010-12-22       Impact factor: 4.330

7.  Polyclonal expansion of TCRBV2- and TCRBV6-bearing T cells in patients with Kawasaki disease.

Authors:  T Yoshioka; T Matsutani; S Iwagami; T Toyosaki-Maeda; T Yutsudo; Y Tsuruta; H Suzuki; S Uemura; T Takeuchi; M Koike; R Suzuki
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

8.  Soluble CD23 antigen in Kawasaki disease and other acute febrile illnesses.

Authors:  T Matsubara; S Furukawa; T Motohashi; K Okumura; K Yabuta
Journal:  Eur J Pediatr       Date:  1995-10       Impact factor: 3.183

9.  Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.

Authors:  S Furukawa; T Matsubara; Y Umezawa; T Motohashi; T Ino; K Yabuta
Journal:  Eur J Pediatr       Date:  1994-09       Impact factor: 3.183

10.  CTLA-4 (CD152) expression in peripheral blood T cells in Kawasaki disease.

Authors:  T Matsubara; R Anwar; M Fujiwara; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.